Biotech Firm Hit With Chancery Suit Over Stock Transactions

Law360 (July 27, 2020, 5:46 PM EDT) -- Industrial biotechnology company Amyris Inc. has been hit with a proposed class action in Delaware Chancery Court seeking to halt an upcoming vote on a stock conversion and $200 million stock offering, saying not enough information has been provided for stockholders to make an informed vote.

Stockholder Alexander Flatischler filed suit Friday against Amyris and its board seeking to halt a scheduled Aug. 14 special meeting of Amyris' stockholders for a vote on the stock transactions. Flatischler contends that the directors have breached their fiduciary duty by not disclosing enough key financial details about the transactions and is seeking to have...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!